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62Background: Onychomycosis, a fungal nail infection, can impact quality of life.Objective:We sought to evaluate the efficacy and safety of tavaborole topical solution, 5% for treatment of
toenail onychomycosis.Methods: In 2 phase-III trials, adults with distal subungual onychomycosis affecting 20% to 60% of a target
great toenail were randomized 2:1 to tavaborole or vehicle once daily for 48 weeks. The primary end point
was complete cure of the target great toenail (completely clear nail with negative mycology) at week 52.
Secondary end points included completely or almost clear nail, negative mycology, completely or almost
clear nail plus negative mycology, and safety.Results: Rates of negative mycology (31.1%-35.9% vs 7.2%-12.2%) and complete cure (6.5% and 9.1% vs
0.5% and 1.5%) significantly favored tavaborole versus vehicle (P # .001). Completely or almost clear nail
rates also significantly favored tavaborole versus vehicle (26.1%-27.5% vs 9.3%-14.6%; P\ .001). Rates of
completely or almost clear nail plus negative mycology (15.3%-17.9% vs 1.5%-3.9%) were significantly
greater for tavaborole versus vehicle (P \ .001). Application-site reactions with tavaborole included
exfoliation (2.7%), erythema (1.6%), and dermatitis (1.3%).Limitations: Duration of follow-up is a limitation.the Department of Dermatology, University of Alabama at
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tavaborole.CAPSULE SUMMARY
d Tavaborole topical solution, 5% is
approved for treatment of toenail
onychomycosis.
d Tavaborole was significantly more
effective than vehicle in treating toenail
onychomycosis in 2 phase-III trials;
incidence of treatment-related
application-site reactions was low.
d The favorable benefit-risk profile makes
tavaborole a reasonable therapeutic
option for toenail onychomycosis.Tavaborole topical solu-
tion, 5% (Anacor Pharmaceu-
ticals, Inc, Palo Alto, CA) is a
novel, boron-based pharma-
ceutical approvedby theFood
and Drug Administration
(FDA) in July 2014 for
the treatment of toenail
onychomycosis caused by
Trichophyton rubrum and T
mentagrophytes.1 Tavaborole
represents a new class of phar-
maceutical antifungal agents
withanovel chemical structure
and mechanism of action
(Fig 1).2-5 Tavaborole targets
fungal cytoplasmic leucyl-
transfer ribonucleic acid (tRNA) synthetase, a member
of a family of aminoacyl-tRNA synthetase enzymes
essential forprotein synthesis.5Theseenzymesmaintain
and translate genetic code within DNA, and possess a
proofreading mechanism that corrects enzymatic
mistakes that occur on a separate, active editing site.
Tavaborole binds to the editing site via its boron atom to
trap leucyl tRNA, preventing its catalytic turnover
and inhibiting protein synthesis. Tavaborole demon-
strates broad-spectrum antifungal activity and more
than 1000-fold greater selectivity for the fungal
leucyl-tRNA synthase than the mammalian leucyl-tRNA
synthetase6; T rubrum and T mentagrophytes isolates
collected from clinical trial patients have not
demonstrated resistance after repeated exposure to
tavaborole.1
The low molecular weight of tavaborole allows a
high amount of penetration through full-thickness
human nail plates.7 Ex vivo permeation studies have
demonstrated tavaborole penetration through
multiple layers of nail polish (data on file, Anacor
Pharmaceuticals, Inc; TER-002-14, ANA-005, 2013).
Phase-I trials showed favorable safety and low
systemic exposure in patients with toenail
onychomycosis,8 and phase-II trials provided
evidence of improved clear nail growth and
negative fungal cultures.9 The objective of the 2
phase-III trials described herein was to evaluate
the efficacy and safety of tavaborole versus
vehicle in adults with distal subungual toenail
onychomycosis.METHODS
Study treatment and
patients
Study treatments inclu-
ded tavaborole and vehicle,
which were applied topically
to the affected nails once
daily for 48 weeks by the
patient. Patients were in-
structed to apply a sufficient
amount of study treatment
on, under, and around
the infected target great
toenail (TGT) and infected
nontarget toenails with a
thin, even layer.
Patients 18 years of age or
older with distal subungual toenail onychomycosis
involving 20% to 60% of at least 1 TGTwere eligible if
they had a positive potassium hydroxide (KOH) wet
mount and positive culture for dermatophytes,
greater than or equal to 3-mm clear nail measured
from the proximal nail fold to the most proximal
visible mycotic border, and distal TGT thickness
3 mm or less. Patients were excluded if they
had proximal subungual or superficial white
onychomycosis, severe disease, dermatophytoma,
exclusively lateral disease, yellow/brown spikes,
coinfection with nondermatophyte fungi, anatomic
abnormalities of the toes or toenails, active tinea
pedis (involving the sides or back of the foot,
interdigital, or plantar) requiring treatment, history
of chronic moccasin-type tinea pedis (involving the
sides or back of the foot), history of other significant
chronic fungal disease, psoriasis, lichen planus,
known immunodeficiency, significant peripheral
vascular disease, known structural heart disease, or
uncontrolled diabetes (hemoglobin A1C $8%).
Patients who used topical antifungals on the toenails
within 4 weeks or systemic antifungals within
24 weeks were also excluded. Recent use of other
topical agents on the toe or toenails, systemic
corticosteroids, or immunomodulatory agents was
not permitted.
Study design
Two phase-III, multicenter, randomized, double-
blind, vehicle-controlled, parallel-group trials of
Fig 1. Tavaborole chemical structure. Tavaborole is a
novel, boron-based pharmaceutical approved for the
treatment of toenail onychomycosis caused by Trichophy-
ton rubrum and T mentagrophytes.1 Tavaborole inhibits
leucyl-tRNA-synthetase, resulting in inhibition of fungal
protein synthesis and termination of fungal cell growth.5
Abbreviations used:
AE: adverse event
FDA: Food and Drug Administration
KOH: potassium hydroxide
TEAE: treatment-emergent adverse event
TGT: target great toenail
tRNA: transfer ribonucleic acid
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United States and Mexico from December 2010 to
November 2012 (study 1; NCT01270971) and the
other at 32 sites in the United States and Canada from
February 2011 to January 2013 (study 2;
NCT01302119). Both studies were conducted in
accordance with ethical principles originating in
the Declaration of Helsinki and in compliance with
the principles of Good Clinical Practice and all
applicable regulatory requirements. The study
protocol was approved by an institutional review
board/independent ethics committee at each site,
and all patients provided written informed consent.
Patients were screened 4 to 10 weeks before
randomization. Eligible patients were randomized
2:1 to receive tavaborole or vehicle, and applied
study treatment to the TGT and all other affected
toenails once daily for 48 weeks. Nail debridement
was not permitted.
Disease involvement was assessed at screening,
baseline (day 1), week 2, week 6, and every 6 weeks
thereafter. At these visits, nail trimming of the
TGT was limited to within 1 mm distal to the
hyponychium or distal groove if needed. Patients
were encouraged not to trim the TGT. All other
toenails were also evaluated for the presence
of onycholysis and subungual hyperkeratosis.
Subungual samples were obtained from the TGT at
screening and every 12 weeks during treatment and
sent to a central mycology laboratory for KOH wet
mount examination with calcofluor white stain and
fungal culture to identify pathogenic fungi including
dermatophyte species. After study treatment
was completed at week 48, follow-up efficacy
assessments were made at week 52.
Efficacy
The primary efficacy end point was complete cure
of the TGT defined as completely clear nail and
negativemycology at week 52. Secondary end points
included completely or almost clear nail of the TGT,
negative mycology of the TGT, and completely or
almost clear nail plus negative mycology, each
determined at week 52. Completely clear nail was
defined as no clinical evidence of onychomycosis
based on a normal toenail plate, no onycholysis, andno subungual hyperkeratosis. Almost clear nail was
defined as no more than minimal evidence of
onychomycosis based on a toenail plate that was
dystrophic or discolored on 10% or less of the distal
aspect, with minimally evident onycholysis and
subungual hyperkeratosis. Negative mycology was
defined as negative KOH wet mount and negative
fungal culture.
Safety
Safety assessments were conducted at each
visit, as was a physical examination evaluating
the frequency and severity of application-site
reactions: burning/stinging, induration/edema,
oozing/crusting, pruritus, erythema, and scaling.
Adverse events (AEs), treatment-emergent AEs
(TEAEs), serious AEs, vital signs, laboratory parame-
ters, and electrocardiographic parameters were
monitored throughout the study.
Statistics
Efficacy parameters were evaluated in the
intent-to-treat population, which included all
randomized patients who received study treatment.
Safety parameters were evaluated in all randomized
patients who received at least 1 dose of study
treatment and had at least 1 postbaseline assessment.
Comparisons between treatment groups for the
primary and secondary efficacy end points were
made using the Cochran-Mantel-Haenszel test
stratified by analysis. A last-observation-carried-
forward approach was used to impute missing
efficacy data. Two-sided hypothesis testing was
conducted using a significance level of .05. AEs
were classified using the Medical Dictionary for
Fig 2. Toenail onychomycosis. Patient disposition. ITT, Intent-to-treat.
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meddra.org). All safety parameters were summarized
descriptively by treatment group.
RESULTS
Patients
The disposition of patients (study 1, N = 594; study
2, N = 604) is depicted in Fig 2. Demographic
and clinical characteristics of the intent-to-treat
population were similar between treatment groups
and generally consistent across the 2 trials (Table I).
Efficacy
Tavaborole was significantly more effective than
vehicle for all primary and secondary efficacy end
points, and produced higher rates of negative culture
and negative KOH at week 52 versus vehicle (Table
II). A significantly greater proportion of patients
achieved complete cure of the TGT at week 52
with tavaborole versus vehicle in study 1 (6.5% vs
0.5%; P = .001) and study 2 (9.1% vs 1.5%; P\.001).
Rates of completely or almost clear nail at week 52
with tavaborole were 26.1% and 27.5% in study 1 and
study 2, respectively, versus 9.3% and 14.6% with
vehicle (both P \ .001). Negative mycology rateswith tavaborole were 31.1% and 35.9% in study 1 and
study 2, respectively, versus 7.2% and 12.2% with
vehicle (both P\ .001). Photographs illustrating a
case with complete cure and a case of almost clear
nail with negative mycology are shown in Fig 3.
The onset of tavaborole clinical activity was
evident by week 24 and generally increased through
the end of treatment at week 48 and the final efficacy
assessment at week 52 (Fig 4). Complete cure of the
TGT was observed as early as week 24 in study 2 and
at week 30 in study 1. Negative culture rates ranged
from 95% atweek 24 to 87% at week 52 in study 1 and
94% at week 24 to 85% at week 52 in study 2.
Negative KOH rates mirrored negative mycology
data.Safety
The incidence of TEAEs with tavaborole versus
vehicle was similar in study 1 (64.4% vs 69.9%,
respectively) and study 2 (57.5% vs 54.0%,
respectively) (Table III). Most TEAEs in patients
receiving tavaborole (95.5%) or vehicle (93.4%)
were reported as mild or moderate in severity. The
most common treatment-related application site
TEAEs with tavaborole in the 2 trials combined
Table II. Efficacy end points at week 52
End point
Study 1 Study 2
Tavaborole
(n = 399)
n (%)
Vehicle
(n = 194)
n (%) P value
Tavaborole
(n = 396)
n (%)
Vehicle
(n = 205)
n (%) P value
Primary end point
Complete cure of TGT* 26 (6.5) 1 (0.5) .001 36 (9.1) 3 (1.5) \.001
Secondary end points
Completely CN or almost CN of TGT 104 (26.1) 18 (9.3) \.001 109 (27.5) 30 (14.6) \.001
Negative mycology of TGT 124 (31.1) 14 (7.2) \.001 142 (35.9) 25 (12.2) \.001
Completely or almost CN plus negative
mycology of the TGT
61 (15.3) 3 (1.5) \.001 71 (17.9) 8 (3.9) \.001
Other end points
Negative culture of TGT 347 (87.0) 93 (47.9) — 338 (85.4) 105 (51.2) —
Negative KOH of TGT 128 (32.1) 17 (8.8) — 147 (37.1) 35 (17.1) —
Completely CN or almost CN of TGT
with negative culture
98 (24.6) 11 (5.7) — 100 (25.3) 19 (9.3) —
CN, Clear nail; KOH, potassium hydroxide wet mount; TGT, target great toenail.
*Completely CN and negative mycology.
Table I. Demographics and baseline characteristics of the intent-to-treat population
Characteristic
Study 1 Study 2
Tavaborole (n = 399) Vehicle (n = 194) Tavaborole (n = 396) Vehicle (n = 205)
Age, y
Mean (SD) 53.6 (12.5) 53.4 (12.3) 55.5 (11.5) 55.4 (11.0)
Range 18-88 19-81 20-81 27-81
Gender, n (%)
Male 324 (81.2) 158 (81.4) 323 (81.6) 174 (84.9)
Female 75 (18.8) 36 (18.6) 73 (18.4) 31 (15.1)
Race
White 316 (79.2) 152 (78.4) 355 (89.6) 183 (89.3)
Black 19 (4.8) 12 (6.2) 21 (5.3) 14 (6.8)
American Indian/Alaska Native 0 (0) 0 (0) 2 (0.5) 1 (0.5)
Asian 2 (0.5) 0 (0) 11 (2.8) 2 (1.0)
Native Hawaiian/Pacific Islander 0 (0) 0 (0) 2 (0.5) 1 (0.5)
Other 62 (15.5) 30 (15.5) 5 (1.3) 4 (2.0)
Country
United States 340 (85.2) 164 (84.5) 315 (79.5) 165 (80.5)
Canada — — 81 (20.5) 40 (19.5)
Mexico 59 (14.8) 30 (15.5) — —
No. of nontarget toenails $10%
affected by onychomycosis
Mean (SD) 3.4 (2.8) 3.8 (2.7) 3.3 (2.8) 3.3 (2.6)
Range 0-9 0-9 0-9 0-9
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dermatitis (1.3%). The majority of TEAEs were
considered not related or unlikely related to study
treatment. The incidence of treatment-related
TEAEs was higher with tavaborole versus vehicle
in study 1 (8.8% vs 2.6%, respectively) and study 2
(3.3% vs 0.5%, respectively) and was attributed to a
higher rate of application-site reactions with tava-
borole versus vehicle in study 1 (7.3% vs 0.5%,respectively) and study 2 (3.0% vs 0%,
respectively). Rates of discontinuations as a result
of AEs occurred at similar rates between treatment
groups (Table III).
There were no deaths in either study. Serious AEs
were reported in 19 patients (2.4%) who received
tavaborole and 10 patients (2.5%) who received
vehicle; none were considered treatment-related.
Results of clinical laboratory and vital assessments
Fig 3. Toenail onychomycosis. Illustrative cases of complete cure of the target great toenail
(top) and almost clear nail with negative mycology (bottom) after treatment with tavaborole for
48 weeks. KOH, Positive potassium hydroxide wet mount.
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drug-related effects were observed on the
electrocardiograms.
DISCUSSION
These findings from 2 phase-III trials demonstrate
that once-daily tavaborole, without adjunctive
debridement, is effective, safe, and well tolerated in
the treatment of toenail onychomycosis. Tavaborole
was significantly more effective than vehicle for all
primary and secondary end points at week 52, with
26% to 28% of patients achieving completely or
almost clear nail; 31% to 36% achieving negative
mycology; 7% to 9% achieving complete cure; and
15% to 18% achieving completely or almost clear nail
and negative mycology. The primary efficacy end
point of complete cure (0% involvement of the nail
plate andnegativemycology)was chosen to enhance
objectivity and is currently a regulatory standard for
assessing the efficacy of antifungal agents for the
treatment of toenail onychomycosis. The safety and
efficacy of tavaborole was demonstrated in both adult
and geriatric patients with a varied degree of disease
severity, as the phase-III clinical trials enrolledpatientsaged18 to88yearswithup to60%clinical involvement
of the TGT. Complete cure rates may not reflect the
full clinical benefitof tavaborole. Althoughcompletely
clear nail represents a definitive clinical cure, an
almost clear nail (#10% affected) represents a
clinically meaningful and successful outcome for
many patients, and is likely the most realistically
achievable outcome considering the residual nail
defects that remain after the infection is cured.
The number of TEAEs reported with tavaborole
was low. Treatment-related TEAEs were localized
to the application site; the most common were
exfoliation, dermatitis, and erythema (1.3%-2.7%).
Rates of discontinuations as a result of TEAEs were
low and comparable with vehicle. Thus, tavaborole
offers a favorable safety and tolerability profile.
Tavaborole is a clear, colorless solution that is easy to
apply, dries quickly, and does not require adjunctive
debridement or removal of prior applications.
The clinical efficacy and safety of tavaborole is
supported by its ability to penetrate the nail plate,
owing to its small size (152 d), hydrophilicity, and
ability to retain pharmacologic antifungal activity in
the presence of keratin.6 In ex vivo nail studies,
Fig 4. Tavaborole efficacy in toenail onychomycosis. Change in efficacy end points over time
from weeks 24 to 52. Each panel shows the percentage of patients achieving the end point at
the indicated time point: complete cure (A); completely clear nail (CN ) or almost CN (B);
negative mycology (C); completely or almost CN plus negative mycology (D); and negative
culture (E). *P # .001 for tavaborole vs vehicle at week 52 for each of the end points assessed.
Vertical lines indicate end of treatment at 48 weeks. Negative mycology was defined as negative
potassium hydroxide wet mount and negative fungal culture. TGT, Target great toenail.
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Table III. Summary of adverse events
Adverse event
Study 1 Study 2
Tavaborole (n = 396)
n (%)
Vehicle (n = 193)
n (%)
Tavaborole (n = 395)
n (%)
Vehicle (n = 202)
n (%)
Patients with $1 TEAEs 255 (64.4) 135 (69.9) 227 (57.5) 109 (54.0)
Most common TEAEs*
Tinea pedis 42 (10.6) 35 (18.1) 53 (13.4) 25 (12.4)
Nasopharyngitis 23 (5.8) 10 (5.2) 27 (6.8) 16 (7.9)
Upper respiratory tract infection 20 (5.1) 8 (4.1) 18 (4.6) 12 (5.9)
Back pain 17 (4.3) 3 (1.6) 7 (1.8) 2 (1.0)
Ingrowing nail 14 (3.5) 1 (0.5) 6 (1.5) 0 (0)
Sinusitis 12 (3.0) 5 (2.6) 6 (1.5) 5 (2.5)
Hypertension 11 (2.8) 8 (4.1) 11 (2.8) 4 (2.0)
Influenza 11 (2.8) 10 (5.2) 2 (0.5) 0 (0)
Headache 10 (2.5) 5 (2.6) 11 (2.8) 7 (3.5)
Muscle strain 8 (2.0) 1 (0.5) 10 (2.5) 6 (3.0)
Most common application site TEAEsy
Exfoliation 16 (4.0) 1 (0.5) 5 (1.3) 0 (0)
Dermatitis 8 (2.0) 0 (0) 2 (0.5) 0 (0)
Erythema 7 (1.8) 0 (0) 6 (1.5) 0 (0)
Pain 5 (1.3) 1 (0.5) 3 (0.8) 0 (0)
Hematoma 2 (0.5) 1 (0.5) 3 (0.8) 2 (1.0)
Discontinuations as a result of TEAEs 1 (0.3) 2 (1.0) 2 (0.5) 1 (0.5)
TEAE, Treatment-emergent adverse event.
*Occurring in $3% of patients in any treatment group.
yOccurring in $1% of patients in any treatment group.
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achieved concentrations above the minimum fungi-
cidal concentration.6,8 Tavaborole application once
daily for 28 days to the toenails of patients with
onychomycosis resulted in nail drug concentrations
substantially above the minimum concentration
required to inhibit 90% of isolates (minimal inhibi-
tory concentration90) of T rubrum.
8 Tavaborole nail
concentrations were 20 times higher than the
minimum fungicidal concentration against the
dermatophytes 3 months after the end of treatment.
Tavaborole demonstrated nail penetration 40-fold
greater than ciclopirox after 14 days of application in
a human cadaver fingernail model.10
In conclusion, these studies demonstrate that
tavaborole, a novel, first-in-class, boron-based
pharmaceutical approved by the FDA for the
treatment of toenail onychomycosis, has a favorable
benefit-risk profile and is an attractive option for the
treatment of onychomycosis of the toenail as a result
of dermatophytes.REFERENCES
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